Progenics Pharmaceuticals Inc. (PGNX): Price and Financial Metrics


Progenics Pharmaceuticals Inc. (PGNX)

Today's Latest Price: $4.10 USD

0.43 (-9.39%)

Updated Jun 19 7:39pm

Add PGNX to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 384 in Biotech

See all "A" rated Strong Buy stocks

PGNX Stock Summary

  • With a price/sales ratio of 9.61, Progenics Pharmaceuticals Inc has a higher such ratio than 87.37% of stocks in our set.
  • With a year-over-year growth in debt of -10.16%, Progenics Pharmaceuticals Inc's debt growth rate surpasses only 20.33% of about US stocks.
  • Revenue growth over the past 12 months for Progenics Pharmaceuticals Inc comes in at 121.09%, a number that bests 95.33% of the US stocks we're tracking.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Progenics Pharmaceuticals Inc are MOSY, UTSI, ATNX, OIIM, and ADTN.
  • Visit PGNX's SEC page to see the company's official filings. To visit the company's web site, go to www.progenics.com.

PGNX Stock Price Chart Interactive Chart >

Price chart for PGNX

PGNX Price/Volume Stats

Current price $4.10 52-week high $6.37
Prev. close $4.53 52-week low $1.89
Day low $3.94 Volume 34,928,301
Day high $4.79 Avg. volume 1,157,679
50-day MA $4.05 Dividend yield N/A
200-day MA $4.61 Market Cap 355.05M

Progenics Pharmaceuticals Inc. (PGNX) Company Bio


Progenics Pharmaceuticals is developing innovative medicines for oncology, with a pipeline that includes several product candidates in later-stage clinical development. The company was founded in 1986 and is based in Tarrytown, New York.


PGNX Latest News Stream


Event/Time News Detail
Loading, please wait...

PGNX Latest Social Stream


Loading social stream, please wait...

View Full PGNX Social Stream

Latest PGNX News From Around the Web

Below are the latest news stories about Progenics Pharmaceuticals Inc that investors may wish to consider to help them evaluate PGNX as an investment opportunity.

Lantheus Completes Merger with Progenics

Lantheus Holdings, Inc. (the "Company") (NASDAQ: LNTH), the parent company of Lantheus Medical Imaging, Inc. ("LMI"), a global leader in the development, manufacture and commercialization of innovative diagnostic imaging agents and products, today announced that it has completed its previously announced merger with Progenics Pharmaceuticals, Inc. ("Progenics") (Nasdaq: PGNX), an oncology company developing innovative medicines and artificial intelligence to find, fight and follow cancer. The merger agreement was first announced on October 2, 2019.

Yahoo | June 22, 2020

Independent Bank Group Set to Join S&P SmallCap 600

Independent Bank Group Inc. (NASD: IBTX) will replace Progenics Pharmaceuticals Inc. (NASD: PGNX) in the S&P; SmallCap 600 effective prior to the opening of trading on Monday, June 22. S&P; Small-Cap 600 constituent Lantheus Holdings Inc. (NASD: LNTH) is acquiring Progenics Pharmaceuticals in a deal expected to be completed on or about June 19 pending final conditions. Post-acquisition, Lantheus Holdings will remain in S&P; SmallCap 600.

Yahoo | June 17, 2020

Progenics Stockholders Approve Merger with Lantheus

NEW YORK, June 16, 2020 -- Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) (“Progenics”), an oncology company developing innovative medicines and artificial intelligence to.

Yahoo | June 16, 2020

SHAREHOLDER ALERT: WeissLaw LLP Investigates Progenics Pharmaceuticals, Inc.

WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Progenics Pharmaceuticals, Inc. ("Progenics" or the "Company") (NASDAQ: PGNX) in connection with the proposed acquisition of the company by Lantheus Holdings, Inc. ("LNTH") (NASDAQ: LNTH). Under the terms of the acquisition agreement, PGNX shareholders will receive 0.31 shares of LNTH for each PGNX share they own, representing implied per-share merger consideration of only $3.96 based on LNTH's May 26, 2020 closing price of $12.77.

Yahoo | May 27, 2020

Progenics to Present Results from the Phase 3 CONDOR Trial of PyL™ (18F-DCFPyL) in Prostate Cancer at the American Society of Clinical Oncology 2020 Virtual Scientific Program

Progenics Pharmaceuticals, Inc. (PGNX), an oncology company developing innovative medicines and artificial intelligence to find, fight and follow cancer, today announced that the results from the Phase 3 CONDOR trial evaluating the diagnostic performance and clinical impact of PyLTM (18F-DCFPyL) in men with biochemical recurrence of prostate cancer will be presented in an oral session at the American Society of Clinical Oncology (ASCO) 2020 Virtual Scientific Program. PyL is the Company’s PSMA-targeted small molecule positron emission tomography (PET) imaging agent designed to visualize prostate cancer.

Yahoo | May 18, 2020

Read More 'PGNX' Stories Here

PGNX Price Returns

1-mo N/A
3-mo N/A
6-mo 5.40%
1-year -27.30%
3-year -30.03%
5-year -47.16%
YTD -19.45%
2019 21.19%
2018 -29.41%
2017 -31.13%
2016 40.95%
2015 -18.92%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.7251 seconds.